New cocktail of drugs shows promise for tough bile duct cancer

NCT ID NCT07392541

Recruiting now Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new combination of four drugs—two standard chemotherapies plus an immunotherapy and a cholesterol drug—in people with advanced bile duct cancer. All 29 participants will receive the same treatment. Researchers will check how many patients see their tumors shrink and how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: adebrelimab (an immunotherapy drug), gemcitabine, cisplatin, and simvastatin
What this could lead to: If this works, it could offer a new treatment option that shrinks tumors and delays cancer growth in people with advanced bile duct cancer.
What could go wrong: This is an early, small exploratory study with only 29 participants. The combination may cause significant side effects, and it is not yet known if it works better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bile duct adenocarcinoma biliary tract cancer extrahepatic bile duct carcinoma gallbladder cancer intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BILIARY TRACT CARCINOMA

Contacts and locations

Locations

Tongji Hospital
RECRUITING

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.